Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach

被引：0
|
作者：
Bullement, Ash [1 ,2 ]
Edmondson-Jones, Mark [1 ,3 ]
Latimer, Nicholas [1 ,2 ]
机构：
[1] Delta Hat, Nottingham, England
[2] Univ Sheffield, SCHARR, Sheffield, England
[3] Univ Leicester, Populat Hlth Sci, Leicester, England
来源：
BMC CANCER | 2024年 / 24卷 / 01期
关键词：
Cost-effectiveness; Non-small cell lung cancer; Partitioned survival model; Hazard ratio; Proportional hazards; Network meta-analysis; Survival analysis;
D O I：
10.1186/s12885-024-12287-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach
    Hui, Wen
    Song, Ruomeng
    Tao, Hongyu
    Gao, Zhixiang
    Zhu, Min
    Zhang, Mingyue
    Wu, Huazhang
    Gong, Daichen
    Zhang, Xiyan
    Cai, Yuanyi
    [J]. BMC CANCER, 2023, 23 (01)
  • [2] Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach
    Hui, Wen
    Gao, Zhixiang
    Zhu, Min
    Wu, Huazhang
    Cai, Yuanyi
    [J]. BMC CANCER, 2024, 24 (01)
  • [3] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    [J]. CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [4] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [5] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [7] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [8] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    [J]. LUNG CANCER, 2018, 124 : 248 - 254
  • [9] A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
    Zheng, Zhiwei
    Zhu, Gaofeng
    Cao, Xueqiong
    Cai, Hongfu
    Zhu, Huide
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (03) : 267 - 273
  • [10] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
12345